Breast cancer in reproductive-age women: oncofertility perspectives, treatment impact, and fertility preservation strategies
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252004Keywords:
Oncofertility, Fertility preservation, Reproductive-age women, Breast cancer, Chemotherapy-induced gonadotoxicityAbstract
Breast cancer remains the most prevalent malignancy among females globally, comprising 12.5% of all cancer cases. While the median age of diagnosis in Western populations is 62 years, India reports a significantly younger median age of approximately 49 years, correlating with its youthful demographic profile. The incidence of breast cancer in women of reproductive age- approximately 19.3 per 100,000- has been rising steadily, necessitating urgent attention to fertility preservation in this population. Cancer treatments such as gonadotoxic chemotherapy, endocrine therapy, and radiation can adversely affect ovarian reserve, delay childbearing, or induce premature ovarian insufficiency. Consequently, fertility preservation has emerged as a crucial component of cancer care for young survivors. Oncofertility, an evolving interdisciplinary field, integrates oncology and reproductive medicine to provide comprehensive fertility counselling and interventions for cancer patients. Despite the growing importance of fertility preservation, barriers such as inadequate referral, limited awareness, financial constraints, and concerns regarding delays in cancer treatment or hormonal stimulation in hormone-positive cases hinder access. The impact of treatment on fertility varies depending on age, ovarian reserve, and treatment modality. Options for fertility preservation include embryo cryopreservation, mature and immature oocyte freezing, ovarian tissue cryopreservation, and temporary ovarian suppression using GnRH agonists. The National Comprehensive Cancer Network (NCCN) recommends early fertility discussions for all premenopausal breast cancer patients. In addition, pregnancy-associated breast cancer (PABC), though rare, presents a clinical challenge due to diagnostic delays and treatment limitations during gestation. As survival rates improve, safeguarding reproductive potential becomes vital to the quality of life of young survivors. Individualized, timely fertility preservation strategies supported by national and international guidelines are key to improving outcomes in reproductive-age women with breast cancer.
Metrics
References
Hampe ME, Rhoton-Vlasak AS. Fertility preservation in breast cancer with case-based examples for guidance. J Assist Reprod Genet. 2020;37(3):717-29. DOI: https://doi.org/10.1007/s10815-019-01665-w
Parmar V. Rising Incidence of Breast Cancer in the Young Fertile Indian Population-a Reality Check. Indian J Surg Oncol. 2018;9(3):296-9. DOI: https://doi.org/10.1007/s13193-018-0800-4
Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, Raza A. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014;15(8):3353-8. DOI: https://doi.org/10.7314/APJCP.2014.15.8.3353
Koo MM, Wagner C, Abel GA, McPhail S, Rubin GP, Lyratzopoulos G. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. Cancer Epidemiol. 2017;48:140-6. DOI: https://doi.org/10.1016/j.canep.2017.04.010
Mehejabin F, Rahman MS. Knowledge and perception of breast cancer among women of reproductive age in Chattogram, Bangladesh: A cross-sectional survey. Health Sci Rep. 2022;5(5):e840. DOI: https://doi.org/10.1002/hsr2.840
Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer. 2014;17(4):301-7. DOI: https://doi.org/10.4048/jbc.2014.17.4.301
Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, Lakshmaiah KC, Kahan Z, et al. Delays in diagnosis and treatment of breast cancer: a multinational analysis. Eur J Public Health. 2014;24(5):761-7. DOI: https://doi.org/10.1093/eurpub/ckt131
Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710-7. DOI: https://doi.org/10.1002/cncr.26459
Anazodo A, Ataman-Millhouse L, Jayasinghe Y, Woodruff TK. Oncofertility-An emerging discipline rather than a special consideration. Pediatr Blood Cancer. 2018;65(11):e27297. DOI: https://doi.org/10.1002/pbc.27297
Hill KA, Nadler T, Mandel R, Burlein-Hall S, Librach C, Glass K, et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation. Clin Breast Cancer. 2012;12(2):127-32. DOI: https://doi.org/10.1016/j.clbc.2012.01.002
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016;34(13):1460-8. DOI: https://doi.org/10.1200/JCO.2015.65.0747
Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1351-8. DOI: https://doi.org/10.1158/1055-9965.EPI-21-1196
Zhao J, Liu J, Chen K, Li S, Wang Y, Yang Y, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113-28. DOI: https://doi.org/10.1007/s10549-014-2914-x
Sonigo C, Beau I, Grynberg M, Binart N. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice. FASEB J. 2019;33(1):1278-87. DOI: https://doi.org/10.1096/fj.201801089R
Zhou L, Xie Y, Li S, Liang Y, Qiu Q, Lin H, et al. Rapamycin Prevents cyclophosphamide-induced Over-activation of Primordial Follicle pool through PI3K/Akt/mTOR Signaling Pathway in vivo. J Ovarian Res. 2017;10(1):56. DOI: https://doi.org/10.1186/s13048-017-0350-3
Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107(1):243-52. DOI: https://doi.org/10.1016/j.fertnstert.2016.10.020
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023;388(18):1645-56. DOI: https://doi.org/10.1056/NEJMoa2212856
Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. Clin Cancer Res. 2012;18(5):1341-51. DOI: https://doi.org/10.1158/1078-0432.CCR-11-2599
Marcu LG, Santos A, Bezak E. Risk of second primary cancer after breast cancer treatment. Eur J Cancer Care (Engl). 2014;23(1):51-64. DOI: https://doi.org/10.1111/ecc.12109
Carlson RW, Jonasch E. NCCN Evidence Blocks. J Natl Compr Cancer Netw. 2016;14(5S):616-9. DOI: https://doi.org/10.6004/jnccn.2016.0177
Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril. 2011;95(5):1535-43. DOI: https://doi.org/10.1016/j.fertnstert.2011.01.003
Lifshitz D, Ben-Haroush A, Meirow D, Orvieto R, Meirman DV, Elbaz L, et al. Letrozole or Tamoxifen co-administration during fertility preservation for patients affected by breast cancer. Reprod Biomed Online. 2025;104878. DOI: https://doi.org/10.1016/j.rbmo.2025.104878
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation. J Clin Oncol. 2005;23(19):4347-53. DOI: https://doi.org/10.1200/JCO.2005.05.037
De Roo C, Tilleman K. In Vitro Maturation of Oocytes Retrieved from Ovarian Tissue: Outcomes from Current Approaches and Future Perspectives. J Clin Med. 2021;10(20):4680. DOI: https://doi.org/10.3390/jcm10204680
Gotschel F, Sonigo C, Becquart C, Sellami I, Mayeur A, Grynberg M. New Insights on In Vitro Maturation of Oocytes for Fertility Preservation. Int J Mol Sci. 2024;25(19):10605.
Gotschel F, Sonigo C, Becquart C, Sellami I, Mayeur A, Grynberg M. New Insights on In Vitro Maturation of Oocytes for Fertility Preservation. Int J Mol Sci. 2024;25(19):10605. DOI: https://doi.org/10.3390/ijms251910605
Rivas Leonel EC, Lucci CM, Amorim CA. Cryopreservation of Human Ovarian Tissue: A Review. Transfus Med Hemotherapy. 2019;46(3):173-81. DOI: https://doi.org/10.1159/000499054
Marci R, Mallozzi M, Di Benedetto L, Schimberni M, Mossa S, Soave I, et al. Radiations and female fertility. Reprod Biol Endocrinol. 2018;16(1):112. DOI: https://doi.org/10.1186/s12958-018-0432-0
Valsamakis G, Valtetsiotis K, Charmandari E, Lambrinoudaki I, Vlahos NF. GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation. Int J Mol Sci. 2022;23(4):2287. DOI: https://doi.org/10.3390/ijms23042287
Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022-33. DOI: https://doi.org/10.1016/j.fertnstert.2019.09.013
Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015;1(8):1145-53. DOI: https://doi.org/10.1001/jamaoncol.2015.2413
Lambertini M, Anserini P, Fontana V, Poggio F, Iacono G, Abate A, Levaggi A, et al. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. BMC Cancer. 2017;17(1):346. DOI: https://doi.org/10.1186/s12885-017-3348-8
Downloads
Published
How to Cite
Issue
Section
